Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis. J of Skin [Internet]. 2018 Feb. 23 [cited 2026 May 22];2(S1):S22. Available from: https://skin.dermsquared.com/skin/article/view/305